Article Type : Short commentary
Authors : Benedetto M and Fazio G
Keywords : Atrial fibrillation; Left atrial appendage closure; percutaneous procedure; Warfarin; Bleeding risk, Guidelines
In the real world experience with large
scale multicentre registries that have proven efficacy and safety of left
atrial appendage closure. Despite the fact that scientific societies agree with
the benefits of left atrial appendage closure if oral anticoagulation is at
high bleeding risk, the current clinical practice guidelines published by the
European Society of Cardiology assigns a low level of recommendation (IIb-B)
for patients with atrial fibrillation who have a contraindication to long-term
oral anticoagulation. It is important to point out that guidelines are
recommendations of clinical behaviour, produced through a systematic process,
in order to assist doctors and patients in deciding the most appropriate
assistance modalities in specific clinical circumstances and that they are not
mandatory. In this review we analizet the importance of this methods in
treatment of atrial fibrillation patients [1].
After being only a surgical procedure in
the late 40s of the previous century1, Since 2002, with the Plaato device,
interventional cardiologists have been able to close the left atrial appendage
in order to prevent, in patients with nonvalvular atrial fibrillation,cerebral
infarction in alternative to oral anticoagulation, especially in patients with
some sort of contraindication to these drugs [2].
From that year there has been a slow but constant growth of the procedure in
terms of number of procedures and in terms of device evolution. In terms of
number of procedures the last United States national registry, we have had an
increase of physicians and hospitals performing left atrila appendage closure
from 30 to more than 1200 and from 20 to over 400, respectively, in the past
two years [3]. Italy confirms this increasing
trend in 2019 with a 16 % increase in the total number of procedures in
comparison to the previous year and a total number of procedures in the same
year that is over 1000, almost tripling since 2014 [4].
The turning point for the procedure was in 2009; in that year we have the
publication of a multicenter randomized clinical trial named PROTECT AF, which
compared the left atrial appendage closure with the Watchman left atrial
appendage occluder device (Boston Scientific, United States) vs conventional
treatment with oral anticoagulation with warfarin. In this trial the
non-inferiority of the percutaneous procedure for the primary composite
endpoint of stroke, cardiovascular death or systemic embolism was proven [5]. And five years later, the PREVAIL trial, a
clinical randomized trial with a similar study design to the PROTECT AF trial,
achieved the same results regarding efficacy; the big difference was a success
rate of 95% and significantly less common complications, demonstrating that
experience in this procedure is of top importance and that skilled operators
are a must, expecially in a procedure where we are not treating an acute
disease, but we are trying to avoid events related to atrial fibrillation [6]. Therefore the procedure has to be performed in
the best setting and the operator experience is a milestone. Moreover the
long-term follow-up results are very positive. In the PROTECT AF trial at
almost 4 year the follow-up demonstrated that the patients have significant
benefit in the composite primary endpoint (8.4% vs 13.9%; hazard ratio = 0.61;
95% confidence interval, 0.38-0.97; P = .04) respect to the control group with
oral anticoagulation with warfarin [7]. But the
main result was that also all-cause mortality improved in the invasive arm in
comparison to the conservative one (12.3% vs 18%; hazard ratio = 0.66; 95%
confidence interval, 0.45-0.98; P = .04). But what happens if we compare left
atrial appendage closure with the new oral anticoagulants. A randomized
clinical trial, the PRAGUE-17, compared LAAO with these novel direct-acting
oral anticoagulants, and proved, even in this case, the non-inferiority of the
interventional procedure compared to novel anticoagulants for what concerns the
prevention of cardiovascular, neurological or hemorrhagic events associated
with atrial fibrillation [8]. These data are
confirmed in the real world experience with large scale multicentre registries
that have proven efficacy and safety of left atrial appendage closure. Among
these the EWOLUTION registry for the Watchman device demonstrated a 98.5%
success rate, and a 2.7% rate of complications [9].
Accordingly the multicentre registry of the Amulet device (Abbott, United
States) demonstrated a 99% success rate and a 3.2% rate of complications [10]. These results are much better that in the early
series telling us once more the importance of operator experience and are
consistent with many other studies published. Despite the fact that scientific
societies agree with the benefits of left atrial appendage closure if oral
anticoagulation is at high bleeding risk, the current clinical practice
guidelines published by the European Society of Cardiology assigns a low level
of recommendation (IIb-B) for patients with atrial fibrillation who have a
contraindication to long-term oral anticoagulation [11].
It is important to point out that guidelines are recommendations of clinical
behaviour, produced through a systematic process, in order to assist doctors
and patients in deciding the most appropriate assistance modalities in specific
clinical circumstances and that they are not mandatory. What is mandatory is to
choose the best treatment option for the specific patient that we have in front
of us and that no clinical trial, however well designed, can consider in all
his peculiarities. Trials are trials and real world is real world and no trial
can ever consider all the variables that a single patient may present. We will
have to wait for the conclusions of 2 ongoing large scale randomized clinical
trials of LAAO vs direct-acting oral anticoagulants, the CHAMPION-AF for the
Watchman Flx, Boston Scientific and the CATALYST, Amulet, Abbott in order to
establish the interventional procedure of left atrial appendage closure against
s technique in patients without contraindications to novel oral
anticoagulation. In conclusion, we can absolutely state that left atrial
appendage closure is safe and effective. The data we have say that its utility
is sure in patients with atrial fibrillation who cannot take oral
anticoagulation to prevent the occurrence of strokes for high bleeding risk. In
some cases the interventional procedure has demonstrated a reduction in mortality
rate compared to oral anticoagulation. It is therefore of great importance to
be aware of this opportunity for patients, avoiding, especially after bleeding
under therapy with novel oral anticoagulants to try another one, rather than
going directly to left atrial appendage closure. In the future results from
upcoming trials should go in this direction making the interventional procedure
the one of choice for effectiveness and safety in our everyday patients with
non valvular atrial fibrillation at high risk of stroke and bleeding and maybe
for cost effectiveness matters, even in patients not at high bleeding risk.
Abbott official Proctor for structural
heart disease interventional treatments.